Vusolimogene Oderparepvec for carcinoma, squamous cell

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 2 registered trials.

Why this status

  1. 8 Aug 2019: Trial registered, NCT04050436
  2. 8 Oct 2019: Trial started, NCT04050436

The trials

NCT04050436: Study Evaluating Cemiplimab Alone and Combined With RP1 in Treating Advanced Squamous Skin Cancer

State
Under way
Phase
Phase 2
People
231 taking part
Started
8 Oct 2019
Primary completion
Sep 2025
Arms
Cemiplimab in combination with RP1
Results
None posted
  1. 8 Aug 2019: Trial registered
  2. 8 Oct 2019: Trial started

NCT05858229: Neo-adjuvant Treatment for Squamous Cell Carcinoma Using Direct Tumor Injection With RP1.

State
Under way
Phase
Phase 1 and Phase 2
People
12 planned
Started
16 Jun 2023
Primary completion
Dec 2025
Arms
Treatment
Results
None posted
  1. 15 May 2023: Trial registered
  2. 16 Jun 2023: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.